Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON). - POSEIDON

Study identifier:D419MC00004

ClinicalTrials.gov identifier:NCT03164616

EudraCT identifier:2017-000920-81

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

Medical condition

Non Small Cell Lung Cancer NSCLC

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin

Sex

All

Actual Enrollment

1186

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 01 Jun 2017
Primary Completion Date: 12 Mar 2021
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria